Prevention of stroke and dementia with statins: Effects beyond lipid lowering

American Journal of Cardiology

Volumn 91, Issue 4 SUPPL., 2003, Pages 23-29

  Vaughan, Carl J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; AMYLOID BETA PROTEIN; ATORVASTATIN; CHOLESTEROL; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PRAVASTATIN; RAS PROTEIN; RHO FACTOR; SIMVASTATIN;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; AORTA ATHEROSCLEROSIS; AORTA THROMBOSIS; ATHEROSCLEROTIC PLAQUE; BRAIN BLOOD FLOW; BRAIN INFARCTION; CAROTID ARTERY THROMBOSIS; CELL GROWTH; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEMENTIA; DISEASE ASSOCIATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; FAMILIAL HYPERCHOLESTEROLEMIA; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMORRHAGIC STROKE; HOMEOSTASIS; HUMAN; MITOGENESIS; MORBIDITY; MORTALITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BINDING; REVIEW; RISK FACTOR; SENESCENCE; SIGNAL TRANSDUCTION; STROKE; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

EID: 0037456569     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)03270-8     Document Type: Review

References (74)

1. Sacco R.L., Benjamin E.J., Broderick J.P., Dyken M., Easton J.D., Feinberg W.M., Goldstein L.B., Gorelick P.B., Howard G., Kittner S.J., et al. American Heart Association Prevention Conference IV Prevention and Rehabilitation of Stroke: Risk Factors. Stroke. 28:1997;1507-1517.
2. National Heart, Lung, and Blood Institute. Morbidity and Mortality: 2000 Chart Book. Bethesda, MD: National Center for Health Statistics; 2000.
3. Wolf P.A., Kannel W.B., Verter J. Current status of risk factors for stroke. Neurol Clin. 1:1983;317-343.
4. Crouse J.R. Effects of statins on carotid disease and stroke. Curr Opin Lipidol. 10:1999;535-541.
5. Atkins D., Psaty B.M., Koepsell T.D., Longstreth W.T. Jr, Larson E.B. Cholesterol reduction and the risk for stroke in men a meta-analysis of randomized, controlled trials. Ann Intern Med. 119:1993;136-145.
6. Helgason C.M., Wolf P.A. American Heart Association Prevention Conference IV Prevention and Rehabilitation of Stroke: Executive Summary. Circulation. 96:1997;701-707.
7. Gaziano J.M., Hebert P.R., Hennekens C.H. Cholesterol reduction weighing the benefits and risks. Ann Intern Med. 124:1996;914-918.
8. Iso H., Jacobs D.R. Jr, Wentworth D., Neaton J.D., Cohen J.D. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 320:1989;904-910.
9. Cholesterol, diastolic blood pressure, and stroke 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet. 346:1995;1647-1653.
10. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
11. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
12. White H.D., Simes R.J., Anderson N.E., Hankey G.J., Watson J.D., Hunt D., Colquhoun D.M., Glasziou P., MacMahon S., Kirby A.C., West M.J., Tonkin A.M. Pravastatin therapy and the risk of stroke. N Engl J Med. 343:2000;317-326.
13. Blauw G.J., Lagaay A.M., Smelt A.H., Westendorp R.G. Stroke, statins, and cholesterol a meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke. 28:1997;946-950.
14. Crouse J.R. III, Byington R.P., Hoen H.M., Furberg C.D. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med. 157:1997;1305-1310.
15. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., Zeiher A., Chaitman B.R., Leslie S., Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes the MIRACL study: a randomized controlled trial. JAMA. 285:2001;1711-1718.
16. Waters D., Schwart G.G., Olsson A.G., Zeiher A.M.F., Ganz P., Ezekowitz M.D., Chaitman B.R., Leslie J., Stern T. Effects of atorvastatin on stroke in patients with unstable angina on non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation. 106:2002;1690-1695.
17. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals a randomised placebo-controlled trial. Lancet. 360:2002;7-22.
18. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature. 343:1990;425-430.
19. Knopp R.H. Drug treatment of lipid disorders. N Engl J Med. 341:1999;498-511.
20. Hall A. The cellular functions of small GTP-binding proteins. Science. 249:1990;635-640.
21. Laufs U., La Fata V., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation. 97:1998;1129-1135.
22. Amarenco P., Cohen A., Tzourio C., Bertrand B., Hommel M., Besson G., Chauvel C., Touboul P.J., Bousser M.G. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med. 331:1994;1474-1479.
23. Dressler F.A., Craig W.R., Castello R., Labovitz A.J. Mobile aortic atheroma and systemic emboli efficacy of anticoagulation and influence of plaque morphology on recurrent stroke. J Am Coll Cardiol. 31:1998;134-138.
24. Furberg C.D., Adams H.P. Jr, Applegate W.B., Byington R.P., Espeland M.A., Hartwell T., Hunninghake D.B., Lefkowitz D.S., Probstfield J., Riley W.A., Young B. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 90:1994;1679-1687.
25. Crouse J.R. III, Byington R.P., Bond M.G., Espeland M.A., Craven T.E., Sprinkle J.W., McGovern M.E., Furberg C.D. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol. 75:1995;455-459.
26. Pitsavos C.E., Aggeli K.I., Barbetseas J.D., Skoumas I.N., Lambrou S.G., Frogoudaki A.A., Stefanadis C.I., Toutouzas P.K. Effects of pravastatin on thoracic aortic atherosclerosis in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 82:1998;1484-1488.
27. Delanty N., Vaughan C.J. Vascular effects of statins in stroke. Stroke. 28:1997;2315-2320.
28. Brown G., Albers J.J., Fisher L.D., Schaefer S.M., Lin J.T., Kaplan C., Zhao X.Q., Bisson B.D., Fitzpatrick V.F., Dodge H.T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 323:1990;1289-1298.
29. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 344:1994;633-638.
30. Waters D., Higginson L., Gladstone P., Kimball B., Le May M., Boccuzzi S.J., Lesperance J. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 89:1994;959-968.
31. Vaughan C.J., Murphy M.B., Buckley B.M. Statins do more than just lower cholesterol. Lancet. 348:1996;1079-1082.
32. Vaughan C.J., Gotto A.M. Jr, Basson C.T. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol. 35:2000;1-10.
33. Carr S., Farb A., Pearce W.H., Virmani R., Yao J.S. Atherosclerotic plaque rupture in symptomatic carotid artery stenosis. J Vasc Surg. 23:1996;755-765.
34. Kimura M., Kurose I., Russell J., Granger D.N. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol. 17:1997;1521-1526.
35. Lehr H.A., Seemuller J., Hubner C., Menger M.D., Messmer K. Oxidized LDL-induced leukocyte/endothelium interaction in vivo involves the receptor for platelet activating factor. Arterioscler Thromb. 13:1993;1013-1018.
36. Weber C., Erl W., Weber K.S.C., Weber P.C. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol. 30:1997;1212-1217.
37. Nikkari S.T., O'Brien K.D., Ferguson M., Hatsukami T., Welgus H.G., Alpers C.E., Clowes A.W. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation. 92:1995;1393-1398.
38. Fukumoto Y., Libby P., Rabkin E., Hill C.C., Enomoto M., Hirouchi Y., Shiomi M., Aikawa M. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation. 103:2001;993-999.
39. Bellosta S., Via D., Canavesi M., Pfister P., Fumagalli R., Paoletti R., Bernini F. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol. 18:1998;1671-1678.
40. Colli S., Eligini S., Lalli M., Camera M., Paoletti R., Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages a novel mechanism of protection against atherosclerosis. Arterioscler Thromb Vasc Biol. 17:1997;265-272.
41. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques implications for plaque stabilization. Circulation. 103:2001;926-933.
42. del Zoppo G.J. The role of platelets in ischemic stroke. Neurology. 51:(suppl 3):1998;S9-S14.
43. Notarbartolo A., Davi G., Averna M., Barbagallo C.M., Ganci A., Giammarresi C., La Placa F.P., Patrono C. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol. 15:1995;247-251.
44. Mayer J., Eller T., Brauer P., Solleder E.M., Schafer R.M., Keller F., Kochsiek K. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol. 64:1992;196-201.
45. 2+ and membrane dynamics in patients with primary hypercholesterolemia effects of pravastatin. Arterioscler Thromb Vasc Biol. 15:1995;759-764.
46. Lacoste L., Lam J.Y., Hung J., Letchacovski G., Solymoss C.B., Waters D. Hyperlipidemia and coronary disease correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 92:1995;3172-3177.
47. Lijnen P., Celis H., Fagard R., Staessen J., Amery A. Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems. J Hypertens. 12:1994;59-64.
48. Nofer J.R., Tepel M., Kehrel B., Wierwille S., Walter M., Seedorf U., Zidek W., Assmann G. Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets a novel mechanism enhancing platelet activity in hypercholesterolemia. Circulation. 95:1997;1370-1377.
49. Wada H., Mori Y., Kaneko T., Wakita Y., Nakase T., Minamikawa K., Ohiwa M., Tamaki S., Tanigawa M., Kageyama S., et al. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hematol. 44:1993;112-116.
50. Aoki I., Aoki N., Kawano K., Shimoyama K., Maki A., Homori M., Yanagisawa A., Yamamoto M., Kawai Y., Ishikawa K. Platelet-dependent thrombin generation in patients with hyperlipidemia. J Am Coll Cardiol. 30:1997;91-96.
51. Liao J.K., Shin W.S., Lee W.Y., Clark S.L. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem. 270:1995;319-324.
52. Endres M., Laufs U., Huang Z., Nakamura T., Huang P., Moskowitz M.A., Liao J.K. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 95:1998;8880-8885.
53. Laufs U., Gertz K., Huang P., Nickenig G., Bohm M., Dirnagl U., Endres M. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke. 31:2000;2442-2449.
54. Laufs U., Endres M., Stagliano N., Amin-Hanjani S., Chui D.S., Yang S.X., Simoncini T., Yamada M., Rabkin E., Allen P.G., et al. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest. 106:2000;15-24.
55. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J., Sessa W.C., Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 6:2000;1004-1010.
56. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 399:1999;601-605.
57. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 6:2000;1399-1402.
58. Bevilacqua M.P., Pober J.S., Majeau G.R., Cotran R.S., Gimbrone M.A. Jr. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med. 160:1984;618-623.
59. Liu T., McDonnell P.C., Young P.R., White R.F., Siren A.L., Hallenbeck J.M., Barone F.C., Feurestein G.Z. Interleukin-1 beta mRNA expression in ischemic rat cortex. Stroke. 24:1993;1746-1751.
60. Chopp M., Zhang R.L., Chen H., Li Y., Jiang N., Rusche J.R. Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats. Stroke. 25:1994;869-876.
61. Pahan K., Sheikh F.G., Namboodiri A.M., Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest. 100:1997;2671-2679.
62. Vaughan C.J., Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke. 30:1999;1969-1973.
63. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., Cottens S., Takada Y., Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 7:2001;687-692.
64. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261:1993;921-923.
65. Hofman A., Ott A., Breteler M.M., Bots M.L., Slooter A.J., van Harskamp F., van Duijn C.N., Van Broeckhoven C., Grobbee D.E. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet. 349:1997;151-154.
66. Bales K.R., Verina T., Dodel R.C., Du Y., Altstiel L., Bender M., Hyslop P., Johnstone E.M., Little S.P., Cummins D.J., et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 17:1997;263-264.
67. Notkola I.L., Sulkava R., Pekkanen J., Erkinjuntti T., Ehnholm C., Kivinen P., Tuomilehto J., Nissinen A. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology. 17:1998;14-20.
68. Jarvik G.P., Wijsman E.M., Kukull W.A., Schellenberg G.D., Yu C., Larson E.B. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease a case-control study. Neurology. 45:1995;1092-1096.
69. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 57:2000;1439-1443.
70. Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drachman D.A. Statins and the risk of dementia. Lancet. 356:2000;1627-1631.
71. Shepherd J., Blauw G.J., Murphy M.B., Cobbe S.M., Bollen E.L., Buckley B.M., Ford I., Jukema J.W., Hyland M., Gaw A., et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol. 84:1999;1192-1197.
72. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P., Runz H., Kuhl S., Bertsch T., von Bergmann K. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A. 98:2001;5856-5861.
73. Kojro E., Gimpl G., Lammich S., Marz W., Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc Natl Acad Sci U S A. 98:2001;5815-5820.
74. Wolozin B. A fluid connection cholesterol and Abeta. Proc Natl Acad Sci U S A. 98:2001;5371-5373.